Doug Drysdale, Alvogen’s CEO, has been named one of Pharmaceutical Executive’s emerging pharma leaders for 2011.
Parsippany, New Jersey, June 15th, 2011 - Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that Doug Drysdale, Alvogen’s CEO, has been named one of Pharmaceutical Executive’s emerging pharma leaders for 2011. The June issue of this prestigious industry publication has identified 30 executives from a range of functions and locations, including Drysdale.
The publication, which is celebrating its 30th anniversary this year, highlighted Doug’s extensive industry experience and “10-80-10” approach to innovation as two of the reasons for his inclusion in the pharma leaders’ list.
“We spend 10 percent of our time planning, 80 percent of our time executing, and 10 percent of our time reflecting on what we could have done differently,” Doug says in the article. “A lot of companies spend 80 percent of their time planning and 20 percent executing. They are thinking too much and too hard about what needs to be done; they get paralyzed by difficult situations.”
Doug also talks about the important of focusing specifically on areas with the most potential value, and then making specific decisions. According to the story: “In the US generics space, Drysdale says, ‘Only generics that are more complex, more high-tech, and have fewer competitors have the real value.’ Outside the US, he says, the value lies in targeting emerging markets.”
Doug concludes: “I don’t think we can claim to have a monopoly on good ideas. But we can execute those ideas faster than our competitors. Having a good idea is not good enough. It’s taking a good idea and turning it into an action that moves you forward — and that comes from speed and decisiveness.”
Commenting on this recognition, Doug Drysdale said: “It is an honor to be included in such a prestigious list of industry executives. I am proud to be able to highlight Alvogen’s unique approach to innovation in this industry-leading publication and thank my colleagues for their support.”
Find the full article here on-line: pharmexec.findpharma.com/